October 17, 2016
Jason Karp’s firm posted a strong third quarter in part due to the collapsing price of a struggling biotech company.
Shares of biotechnology firm MannKind Corp., which specializes in therapeutic products for diabetes and has been in free fall lately, plummeted another 8 percent or so on Friday, to close at a new low of about $0.50 per share. This …
*free trial allows access to online content excluding research, rankings and data.
Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.
Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.
How will hedge funds finish 2017?
View previous results
All material subject to strictly enforced copyright laws. ©
Euromoney Institutional Investor PLC.
Sorry, you are not allowed to print this article.
Please contact us if you have any inquiry.